A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...

Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...

The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.

More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...

Drug developers have successfully tackled general anxiety with a number of innovations. But social anxiety disorder, which can trigger debilitating fear, self-consciousness or nervousness during ...

CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave ...